PedAM
Pediatric Disease Annotations & Medicines
| Disease | arteriosclerosis |
| Phenotype | C0022658|kidney disease |
| Sentences | 38 |
| PubMedID- 26287243 | One of the possible causes of enhanced atherosclerosis in patients with chronic kidney disease (ckd) is the accumulation of uremic toxins. |
| PubMedID- 20190248 | Background: chronic kidney disease (ckd) is associated with accelerated atherosclerosis and an inadequate inflammatory response which may account for the high morbidity and mortality observed in this population. |
| PubMedID- 23291030 | Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management. |
| PubMedID- 26042415 | Background: chronic kidney disease (ckd) is associated with accelerated atherosclerosis and an increased risk of adverse cardiovascular disease (cvd) outcomes. |
| PubMedID- 23883412 | Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease. |
| PubMedID- 23644777 | Comment to sylwia olechnowicz-tietz et al.: the risk of atherosclerosis in patients with chronic kidney disease. |
| PubMedID- 23828708 | Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease. |
| PubMedID- 25288367 | Moreover, it has been noted that tissue et-1 concentration is more important than serum et-1 in predicting atherosclerosis in patients with chronic kidney disease (noshad et al. |
| PubMedID- 25767908 | The method is rapid, accurate and reproducible, and was successfully applied to a pilot study of markers of atherosclerosis in patients with kidney disease who underwent successful kidney transplantation. |
| PubMedID- 24188108 | These compounds are currently considered as likely players in atherosclerosis in patients with chronic kidney disease [15]. |
| PubMedID- 23483304 | The risk of atherosclerosis in patients with chronic kidney disease. |
| PubMedID- 25360490 | Cyanate is a uremic toxin responsible for the carbamylation of proteins, which has been implicated as playing a key role in accelerating the progression of atherosclerosis in patients with chronic kidney disease. |
| PubMedID- 20940700 | The development of atherosclerosis in patients with chronic kidney disease (ckd) is severely accelerated leading to life-threatening cardiovascular (cv) events and its pathogenesis is different from that in the general population. |
| PubMedID- 20602330 | Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. |
| PubMedID- 21071957 | Changes mediated by oxidative stress are thought to be involved with atherosclerosis in patients with chronic kidney disease (ckd). |
| PubMedID- 25069821 | Scope: hyperhomocysteinemia (hhcy) is associated with kidney disease and leads to atherosclerosis and thrombosis. |
| PubMedID- 19924100 | Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. |
| PubMedID- 24067603 | Aim: both oxidized ldl and carbamylated ldl are considered important for initiating atherosclerosis in patients with end-stage kidney disease through vascular endothelial cell dysfunction or injury. |
| PubMedID- 23835686 | Less is known about the association of diabetic kidney disease with subclinical atherosclerosis, i.e., whether these processes develop sequentially or in parallel. |
| PubMedID- 25728732 | Background: chronic kidney disease (ckd) is associated with accelerated atherosclerosis and adverse cardiovascular outcomes, but mechanisms are unclear. |
| PubMedID- 22907629 | Low serum pancreatic enzyme levels predict mortality and are associated with malnutrition-inflammation-atherosclerosis syndrome in patients with chronic kidney disease. |
| PubMedID- 23052640 | Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. |
| PubMedID- 20592243 | Chronic kidney disease (ckd) is associated with accelerated atherosclerosis and cardiovascular disease, which is largely mediated by oxidative stress. |
| PubMedID- 25782215 | Studies indicate that deficiency of vitamins and antioxidants in diet and also enhanced oxidative stress are cause of many complications for example: accelerated process of arteriosclerosis in patients with chronic kidney disease. |
| PubMedID- 26427152 | Conclusions: our findings suggest that monitoring serum fgf-23 may be useful as a non-invasive indicator of subclinical atherosclerosis in patients with chronic kidney disease. |
| PubMedID- 25957119 | The aim of this study was to examine the changes in the clinical characteristics and carotid atherosclerosis of patients with end-stage kidney disease (eskd) over the last 9 years. |
| PubMedID- 23599704 | Background/aims: previous studies have shown the presence of high levels of glycoxidation and lipid peroxidation products in association with atherosclerosis in patients with end-stage kidney disease. |
| PubMedID- 23023631 | This association is partly explained by monckeberg's medial calcification, a characteristic atherosclerosis present in patients with advanced chronic kidney disease. |
| PubMedID- 21823040 | Adiponectin (adpn) counteracts the inflammatory response of the endothelium, which plays an important role in the development of atherosclerosis in patients with chronic kidney disease (ckd). |
| PubMedID- 20844474 | Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. |
| PubMedID- 22383985 | The increased mmp production seems to correlate more with the increased thrombotic incidence and atherosclerosis observed in patients with kidney disease. |
| PubMedID- 22781707 | Aims: indoxyl sulfate, a uremic toxin, is considered a risk factor for arteriosclerosis in patients with chronic kidney disease (ckd). |
| PubMedID- 22937042 | Impaired hemostasis coexists with accelerated atherosclerosis in patients with chronic kidney disease (ckd). |
| PubMedID- 21226275 | atherosclerosis is common in patients with chronic kidney disease (ckd), and cardiovascular disease (cvd) represents a major cause of death in these patients, especially, in patients with end-stage renal disease(esrd). |
| PubMedID- 23652447 | Carotid atherosclerosis in kidney disease. |
| PubMedID- 24085020 | Background and purpose: we aimed to clarify the association of chronic kidney disease (ckd) with carotid atherosclerosis and the impact of ckd on carotid atherosclerosis according to blood pressure categories in an urban general population. |
| PubMedID- 23319980 | Fibrinogen is an acute phase reactant and is also associated with progression of atherosclerosis in patients with chronic kidney disease [21]. |
| PubMedID- 20308998 | Chronic kidney disease (ckd) is associated with development of atherosclerosis and premature death from cardiovascular disease. |
Page: 1